The pharmacokinetics and pharmacodynamics of high-dose paclitaxel monotherapy (825 mg/m2 continuous infusion over 24 h) with hematopoietic support in women with metastatic breast cancer Academic Article Article uri icon

Overview

MeSH Major

  • Antineoplastic Agents
  • Breast Neoplasms

abstract

  • HDP (825 mg/m2 continuous infusion over 24 h) did not appear to be myeloablative. The degree of neurotoxicity subsequent to HDP was associated with the degree of baseline neuropathy but was not predictable from pharmacokinetic parameters.

publication date

  • July 31, 2001

Research

keywords

  • Academic Article

Identity

Digital Object Identifier (DOI)

  • 10.1007/s002800000193

PubMed ID

  • 11221961

Additional Document Info

start page

  • 45

end page

  • 50

volume

  • 47

number

  • 1